| Cat.No. | Name | Information |
|---|---|---|
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M31199 | CDK-IN-2 | CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM. |
| M31196 | CDK12-IN-2 | CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM). CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12. |
| M31193 | 5,6-Dichlorobenzimidazole riboside | 5,6-Dichlorobenzimidazole riboside is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II and CDKs. 5,6-Dichlorobenzimidazole riboside trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells. |
| M30106 | NU6102 | NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM). |
| M29171 | CDK2-IN-4 | CDK2-IN-4 is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM). |
| M28894 | Samuraciclib | Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects. |
| M28667 | (±)-Enitociclib | (±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. |
| M28663 | SEL120-34A HCl | SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity. |
| M28381 | NSC 625987 | NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2. |
| M21409 | FN-1501 | FN-1501 is a potent inhibitor of Fms-like receptor tyrosine kinase 3 (FLT3) and cyclin-dependent kinase (CDK), and the IC50 for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3 with IC50s of 2.47, 0.85, 1.96 and 0.28 nM, respectively. |
| M21148 | (R)-CR8 trihydrochloride | (R)-CR8 trihydrochloride, one of the isomers of CR8, is a potent CDK1/2/5/7/9 inhibitor with anti-proliferative and pro-apoptotic effects on CML cell lines. (R)-CR8 trihydrochloride inhibited CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM ), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). |
| M20882 | G1T38 | Lerociclib (G1T38) is a novel, potent, selective, and orally bioavailable CDK4/6 inhibitor with IC50 values of 0.001 μM, 0.002 μM and 0.028 μM for CDK4, CDK6 and CDK9 respectively. |
| M20751 | BRD6989 | BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 selectively binds a complex of CDK8 with an IC50 of ~200 nM. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA). |
| M20705 | AS2863619 | AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells. |
| M20671 | SGC-GAK-1 | SGC-GAK-1 is a potent, selective, and cell-active inhibitor of cyclin G-associated kinase (GAK) with Ki value of 3.1 nM and >50-fold selectivity over nearest kinase. |
| M13618 | XL413 hydrochloride | XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM. |
| M13615 | Simurosertib | Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM. Simurosertib has anti-cancer activity. |
| M13614 | Senexin A | Senexin A is a CDK8 inhibitor with an IC50 of 280 nM. |
| M13611 | RGB-286638 free base | RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM. |
| M13610 | PHA-767491 hydrochloride | PHA-767491 hydrochloride is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
